Promega BioSciences, LLC
Resin Feasibility Study
Process scale-up of a bioassay resin.
Promega is a global leader in providing technical solutions and support to life scientists who advance disease diagnoses and treatments, discover new therapeutics, and use genetics and DNA testing for human identification. One of Promega’s unique products is a magnetic affinity bead with high specificity and high binding capacity for immunoglobulins. To meet increasing demand for these beads, Promega engaged AEI to study the feasibility of scaling the production process from lab hood to pilot plant size equipment.
Material handling challenges in the resin production process include fibrous solids, high-viscosity gels, flammables, and friable particles. The batch cycle is over a week in duration, with a diffusion-limited reaction conducted in a reverse-phase emulsion. In addition to the process complexity, the facility for the scaled process presented spatial and utility constraints. AEI’s analysis ultimately recommended unit operations for the proposed pilot scale, while providing potential sizing and arrangement of industrial scale equipment.
Promega Biosciences a biological research company, develops and manufactures synthetic organic chemistry products. Promega holds a diverse portfolio including bioluminescent compounds and protein labeling and capture technology.